Abstract Details

Title The ALIAS Trial: A Phase III Randomized Multicenter Clinical Trial of Albumin-Neuroprotection in Acute Ischemic Stroke: Rationale, Study Design, and Progress Report

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) (-)

Poster/Presentation
Number 006

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Myron D. Ginsberg, MD, FAAN (University of Miami Miller School of Medicine)	No disclosure on file
Michael D. Hill, MD (University of Calgary)	Dr. Hill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Dr. Hill has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sun Pharma. Dr. Hill has received stock or an ownership interest from Circle Neurovascular.
Yuko Palesch	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��

��ɫ��

Abstract Details

��ɫ����

��ɫ����

��ɫ��

��ɫ��